Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MyBacteriophage is an innovative biotechnology company focused on developing personalized bacteriophage therapies to combat the global threat of antibiotic-resistant bacterial infections. The company utilizes a proprietary platform to identify, isolate, and characterize specific phages that target a patient's unique bacterial strain, offering a highly precise alternative to traditional broad-spectrum antibiotics. By leveraging advanced genomic sequencing and rapid screening technologies, MyBacteriophage aims to provide tailored treatments for chronic and life-threatening infections. Their approach focuses on high-need areas such as cystic fibrosis, prosthetic joint infections, and multi-drug resistant wound infections.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MyBacteriophage.